These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 14724308)

  • 41. Post-procedural patient management: prevention and management of bleeding complications.
    Aguirre F
    J Invasive Cardiol; 1994; 6 Suppl A():34A-37A; discussion 54A-56A. PubMed ID: 10155093
    [No Abstract]   [Full Text] [Related]  

  • 42. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 43. Routine use of abciximab in coronary stenting?
    Stables RH
    Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
    [No Abstract]   [Full Text] [Related]  

  • 44. Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
    Steinhubl SR; Moliterno DJ
    Heart Vessels; 1997; Suppl 12():148-55. PubMed ID: 9476567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimal treatment of acute coronary syndromes--an evolving strategy.
    Boden WE; McKay RG
    N Engl J Med; 2001 Jun; 344(25):1939-42. PubMed ID: 11419433
    [No Abstract]   [Full Text] [Related]  

  • 46. [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
    Niessner A; Niessner H; Huber K
    Herz; 2001 Apr; 26 Suppl 1():36-41. PubMed ID: 11349625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
    Campbell P
    N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228
    [No Abstract]   [Full Text] [Related]  

  • 48. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
    Madan M; Berkowitz SD; Christie DJ; Jennings LK; Smit AC; Sigmon KN; Glazer S; Tcheng JE
    Am Heart J; 2001 Feb; 141(2):226-33. PubMed ID: 11174336
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab.
    Frilling B; Zahn R; Fraiture B; Mark B; Dönges K; Becker T; Siegler KE; Seidl K; Rustige J; Senges J
    Am J Cardiol; 2002 Feb; 89(4):450-2. PubMed ID: 11835927
    [No Abstract]   [Full Text] [Related]  

  • 50. Percutaneous revascularization for unstable angina in the elderly.
    Hirsch H; Lazar J; Marzo KP; Steingart RM
    Coron Artery Dis; 2000 Jun; 11(4):315-22. PubMed ID: 10860174
    [No Abstract]   [Full Text] [Related]  

  • 51. Platelet GP IIb/IIIa inhibition in myocardial infarction treated by coronary stenting: ready for prime time.
    Anderson HV
    J Invasive Cardiol; 2000 Mar; 12(3):140-1. PubMed ID: 10877555
    [No Abstract]   [Full Text] [Related]  

  • 52. Aspirin in patients with coronary artery disease: is it simply irresistible?
    Nair GV; Davis CJ; McKenzie ME; Lowry DR; Serebruany VL
    J Thromb Thrombolysis; 2001 Apr; 11(2):117-26. PubMed ID: 11406726
    [No Abstract]   [Full Text] [Related]  

  • 53. Economics of coronary stenting and GPIIb/IIIa blockade.
    Weintraub WS
    Eur Heart J; 2001 Aug; 22(16):1366-8. PubMed ID: 11482914
    [No Abstract]   [Full Text] [Related]  

  • 54. Antiplatelet therapy.
    Gershlick AH
    Hosp Med; 2000 Jan; 61(1):15-23. PubMed ID: 10735148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor.
    Frishman WH; Burns B; Atac B; Alturk N; Altajar B; Lerrick K
    Am Heart J; 1995 Oct; 130(4):877-92. PubMed ID: 7572600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiplatelet therapy in coronary artery disease: review and update of efficacy studies.
    Tisdale JE
    Am J Health Syst Pharm; 1998 Oct; 55(19 Suppl 1):S8-16. PubMed ID: 9784797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?
    Harding SA; Boon NA; Flapan AD
    Heart; 2002 Jul; 88(1):11-4. PubMed ID: 12067932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Avoidance of adverse events in restenotic lesions with abciximab?
    Linnemeier TJ
    J Invasive Cardiol; 2000 Nov; 12(11):545-6. PubMed ID: 11060564
    [No Abstract]   [Full Text] [Related]  

  • 59. New approaches to the pharmacological treatment of angina.
    Denktas AE; Bayes-Genis A; Schwartz RS
    Curr Opin Pharmacol; 2001 Apr; 1(2):151-8. PubMed ID: 11714089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Revascularization techniques in acute myocardial infarction.
    Gorman RC; Gorman JH
    N Engl J Med; 2000 Dec; 343(24):1815. PubMed ID: 11185605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.